Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Research graph
References from Intratumoral C3ar/C5ar1 Antagonists Imbedded in an In Situ Forming Implant Can Robustly Suppress Solid Tumors. Local targets link to admitted publications; unresolved targets remain external evidence.
Genetic variants in complement-related genes: Potential implications for cancer risk and progression
10.1016/j.imbio.2025.153100 · 2025 · External reference
Interplay between the complement system and other immune pathways in the tumor microenvironment
10.1016/j.smim.2025.101951 · 2025 · External reference
Harnessing complement biomarkers for precision cancer care
10.1016/j.smim.2025.101963 · 2025 · External reference
Pro- and Anti-Inflammatory Role of Complement in Cancer
10.1002/eji.202451767 · 2025 · External reference
Decay-accelerating factor moduLates induction of T cell immunity
10.1084/jem.20041967 · 2005 · External reference
Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation
10.1111/j.1600-6143.2009.02723.x · 2009 · External reference
Locally produced complement fragments C5a and C3a provide both costimuLatory and survival signals to naive CD4+ T cells
10.1016/j.immuni.2008.02.001 · 2008 · External reference
The complement system as a target in cancer immunotherapy
10.1002/eji.202350820 · 2024 · External reference
IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production
10.4049/jimmunol.180.9.5882 · 2008 · External reference
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells
10.1126/science.aad1210 · 2016 · External reference
Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis
10.1182/blood-2008-04-151068 · 2008 · External reference
Absence of signaling into CD4(+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3(+) reguLatory T cells
10.1038/ni.2499 · 2013 · External reference
CD55 Is Essential for CD103(+) Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity
10.1016/j.ajpath.2019.04.008 · 2019 · External reference
C5aR1 reguLates migration of suppressive myeloid cells required for costimuLatory blockade-induced murine allograft survival
10.1111/ajt.15072 · 2019 · External reference
Local and Cell-intrinsic complement: The new player in cancer progression
10.1016/j.smim.2025.101976 · 2025 · External reference
Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis
10.1053/gast.2002.37075 · 2002 · External reference
The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells
10.1074/jbc.m310643200 · 2004 · External reference
RTK signaling requires C3ar1/C5ar1 and IL-6R joint signaling to repress dominant PTEN, SOCS1/3 and PHLPP restraint
10.1096/fj.201900677r · 2020 · External reference
VEGFR2 survival and mitotic signaling depends on joint activation of associated C3ar1/C5ar1 and IL-6R-gp130
10.1242/jcs.219352 · 2019 · External reference
10.3390/biology14070756
10.3390/biology14070756 · External reference
VascuLar Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive HepatocelluLar Carcinoma After Combination Therapy with Anti-Programmed Death-Ligand 1 and Anti-VascuLar Endothelial Growth Factor-A Antibodies
10.1016/j.gastha.2025.100778 · 2026 · External reference
Microenvironmental reguLation and remodeling of breast cancer angiogenesis: From basic mechanisms to clinical therapeutic implications
10.1007/s12672-025-03797-1 · 2025 · External reference
The intrinsic complement reguLator decay-accelerating factor moduLates the biological response to vascuLar injury
10.1161/atvbaha.110.205559 · 2010 · External reference
Navigating the metabolic landscape of reguLatory T cells: From autoimmune diseases to tumor microenvironments
10.1016/j.coi.2024.102511 · 2025 · External reference
Unleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity
10.1016/j.intimp.2024.113952 · 2025 · External reference
ModuLation of the antitumor immune response by complement
10.1038/ni.1655 · 2008 · External reference
Unwelcome complement
10.1158/0008-5472.can-09-1918 · 2009 · External reference
TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement
10.4049/jimmunol.1700339 · 2017 · External reference
In situ forming parenteral drug delivery systems: An overview
10.1016/j.ejpb.2004.03.003 · 2004 · External reference
PLGA and cancer: A comprehensive patent-based review on the present state of art
10.1080/20468954.2025.2470103 · 2025 · External reference
New methods for direct delivery of chemotherapy for treating brain tumors
2006 · External reference
Management of locally advanced prostate cancer: Past, present, future
10.1016/j.juro.2006.06.079 · 2006 · External reference
Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial
10.1001/jama.296.19.2329 · 2006 · External reference
Polymeric implants for cancer chemotherapy
10.1016/s0169-409x(97)00036-7 · 1997 · External reference
Biodegradable injectable in situ forming drug delivery systems
10.1016/s0168-3659(02)00008-1 · 2002 · External reference
10.3390/antib14010016
10.3390/antib14010016 · External reference
10.3389/fimmu.2025.1515027
10.3389/fimmu.2025.1515027 · External reference
MuLtimodality Imaging and Immune-Related Adverse Events During Immune Checkpoint Inhibitors Treatment: Where Do We Stand?
10.1111/echo.70115 · 2025 · External reference
Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: A systematic review and meta-analysis
10.1007/s10555-025-10246-6 · 2025 · External reference
Antigen-presenting cell-derived complement moduLates graft-versus-host disease
10.1172/jci61019 · 2012 · External reference
Critical Role of CD55 in Controlling Wound Healing
10.4049/jimmunol.2300628 · 2024 · External reference
Expression of functional receptors for human C5a anaphylatoxin (CD88) on the human hepatocelluLar carcinoma cell line HepG2. StimuLation of acute-phase protein-specific mRNA and protein synthesis by human C5a anaphylatoxin
10.4049/jimmunol.155.1.308 · 1995 · External reference
Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88)
10.1158/1078-0432.ccr-12-1204 · 2013 · External reference
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression
10.4049/jimmunol.1201654 · 2012 · External reference
C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA
10.18632/oncotarget.12656 · 2016 · External reference
C5a stimuLates the proliferation of breast cancer cells via Akt-dependent RGC-32 gene activation
10.3892/or.2014.3489 · 2014 · External reference
Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness
10.3892/or.2014.3341 · 2014 · External reference
C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation
10.3892/or.2014.3420 · 2014 · External reference
Opposing roles for complement component C5a in tumor progression and the tumor microenvironment
10.4049/jimmunol.1200846 · 2012 · External reference
Autocrine effects of tumor-derived complement
10.1016/j.celrep.2014.02.014 · 2014 · External reference
Myeloid tumors and antitumor innate immunity
2025 · External reference
10.3389/fimmu.2025.1608215
10.3389/fimmu.2025.1608215 · External reference
Positive and negative roles of myeloid cells in cancer immunotherapy
10.1136/jitc-2025-012743 · 2025 · External reference
Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies
10.1016/j.gene.2025.149772 · 2025 · External reference
10.3389/fimmu.2025.1623436
10.3389/fimmu.2025.1623436 · External reference
Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia
10.1007/s00432-025-06315-6 · 2025 · External reference
10.3390/cancers17213441
10.3390/cancers17213441 · External reference
Unresolved reference
External reference